A new drug, PIPE-307: New Multiple Sclerosis Drug Regenerates Myelin, Improves Movement

 https://neurosciencenews.com/myelin-movement-ms-neuropharmacology-37518/

Summary: A new drug, PIPE-307, shows promise in reversing multiple sclerosis (MS) damage by promoting myelin regeneration around nerve cells, potentially restoring movement and function.

Developed by researchers, this innovative therapy targets a specific receptor, M1R, and has already demonstrated success in animal models. PIPE-307 is currently in Phase II clinical trials, offering hope for a groundbreaking treatment that could stop and even heal the damage caused by MS.

This novel approach could transform the future of MS therapy by addressing both symptoms and underlying damage.

 

New treatment may stop and potentially reverse some nerve damage in MS

https://www.medicalnewstoday.com/articles/new-treatment-may-stop-potentially-reverse-nerve-damage-ms#Early-progress-could-give-hope-to-MS-patients

 The newly developed drug — PIPE-307 — blocks the M1R receptor, allowing the OPCs to differentiate into oligodendrocytes that can then form new myelin sheaths.